<DOC>
	<DOCNO>NCT00174759</DOCNO>
	<brief_summary>Primary objective : To evaluate whether clopidogrel 75 mg o.d . versus placebo ( background ASA 75-100 mg/d ) lead increase rate primary patency , limb salvage survival , patient receive knee bypass graft treatment PAD . Secondary objective : Comparison , two treatment group , : - Primary patency , - Assisted primary patency , - Cardiovascular death / myocardial infarction / stroke / amputation ankle . - Ankle Brachial Pressure Index ( ABPI ) change baseline</brief_summary>
	<brief_title>CASPAR : Clopidogrel Acetyl Salicylic Acid Bypass Surgery Peripheral ARterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>A patient eligible inclusion study 24 day surgery follow criterion fulfil : Informed consent obtain ; Chronic background treatment daily ASA , whatever dose , start least 4 week surgery . A window day without ASA surgery acceptable , accord local practice . Postrandomization use ASA must 75 100 mg/day . Unilateral knee bypass graft ( i.e . distal anastomosis level knee joint ) atherosclerotic PAD within previous 4 day ; Demonstration initial patency index graft objective measurement ( e.g . intraoperative Doppler scanning , flow measurement , angiography , Duplex scan ) bypass surgery , surgery time randomization ; No clinical evidence graft occlusion time randomization . Exclusion criterion : PAD medical/surgical history Onset PAD symptom age 40 year Nonatherosclerotic vascular disease ( e.g . Buerger 's disease , popliteal entrapment syndrome ) Patient receive aortobifemoral , iliacfemoral crossover ( femoralfemoral ) graft , undergo peripheral transcutaneous angioplasty ( PTA ) , without stenting , surgery . Medical history relate bleeding risk Current active bleeding surgical site Withdrawal epidural catheter le 12 hour randomization Current active bleeding increase risk bleeding , severe hepatic insufficiency , proliferative diabetic retinopathy , peptic ulceration , bleed diathesis coagulopathy Peptic ulceration within 12 month randomization Previous current intracranial hemorrhage hemorrhagic stroke , previous stroke diagnosis hemorrhagic stroke exclude Any history severe spontaneous bleed gastrointestinal bleeding , gross hematuria , intraocular bleed Other medical condition Previous disable stroke ( severe cerebral deficit patient bedridden demented ) NYHA Class IV heart failure Uncontrolled hypertension : Systolic Blood Pressure ( SBP ) &gt; 180 mm Hg , Diastolic Blood Pressure ( DBP ) &gt; 100 mm Hg</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>